Rapport Therapeutics, Inc. (RAPP) insider trading

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Third Rock Ventures V, L.P. entity

Director

—

$34.39M (5) scheduled

−$34.39M

8,678,314

18.09%

$182.24M

+7.1%

James Healy

Director

$20.36M (4)

—

+$20.36M

2,873,888

5.99%

$60.35M

+50.9%

Abraham Ceesay

Chief Executive Officer

—

$5.99M (36) scheduled

−$5.99M

573,222

1.19%

$12.04M

−29.3%

Krishnaswamy Yeleswaram

Chief Development Officer

—

$4.46M (11) scheduled

−$4.46M

195,862

0.4082%

$4.11M

−32.7%

Cheryl Gault

Chief Operating Officer

—

$1.24M (10) scheduled

−$1.24M

139,914

0.2916%

$2.94M

−11.4%

David Bredt

Chief Scientific Officer

—

$1.14M (10) scheduled

−$1.14M

393,075

0.8193%

$8.25M

−23.5%

Steven M Paul

Director

$974.28K (1)

—

+$974.28K

596,688

1.24%

$12.53M

+14.9%

John Maraganore

Director

$248.89K (2)

—

+$248.89K

9,411

0.0196%

$197.63K

—

Troy A. Ignelzi

Chief Financial Officer

$143.55K (1)

—

+$143.55K

15,500

0.0323%

$325.50K

—

Wendy B. Young

Director

$99.99K (1)

—

+$99.99K

13,289

0.0277%

$279.07K

—

Paul M Silva

Director

$99.64K (1)

—

+$99.64K

3,680

0.0077%

$77.28K

—

Ramiro Sanchez

Director

$98.48K (1)

—

+$98.48K

3,600

0.0075%

$75.60K

—

Reid M Huber

Director

—

20,400

0.0425%

$428.40K

—

Rapport Therapeutics, Inc.

What the insiders did Net buying

By person